Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04075747 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
A Phase 1 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT04075747 is a Phase 1 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 57 participants.
The verdict
NCT04075747, a Phase 1 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
JZP025-101 is an open-label, multicenter, multi-arm, nonrandomized phase 1b master trial to determine the recommended phase 2 dose (RP2D) of CPX-351 when administered in combination with various targeted agents in previously untreated subjects with Acute Myeloid Leukemia (AML) who are fit to receive intensive chemotherapy (ICT). Subjects will be assigned to treatment arms based on results of AML mutation testing.
Interventions
- DRUG Venetoclax
- DRUG Midostaurin
- DRUG Enasidenib
- DRUG CPX-351
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2023-09-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04075747
The ClinicalTrials.gov registry entry for NCT04075747 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Venetoclax is the first listed.
NCT04075747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04075747 about?
NCT04075747 is a clinical study titled "A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia". JZP025-101 is an open-label, multicenter, multi-arm, nonrandomized phase 1b master trial to determine the recommended phase 2 dose (RP2D) of CPX-351 when administered in combination with various targeted agents in previously untreated subjects with Acute Myeloid Leukemia (AML) who are fit to receive...
What is the current status of trial NCT04075747?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2019-12-02. Estimated completion is 2023-09-12.
What interventions are being tested in trial NCT04075747?
The interventions under investigation include: Venetoclax (DRUG), Midostaurin (DRUG), Enasidenib (DRUG), CPX-351 (DRUG).
Who is sponsoring clinical trial NCT04075747?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.